BrightGene Bio-Medical Technology Co., Ltd. (688166) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BrightGene Bio-Medical Technology Co., Ltd.

Why is BrightGene Bio-Medical Technology Co., Ltd. ?

High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Net Sales has grown by an annual rate of 11.00% and Operating profit at -25.90% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times
The company has been able to generate a Return on Equity (avg) of 9.15% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of 11.00% and Operating profit at -25.90% over the last 5 years

The company has declared negative results for the last 6 consecutive quarters

NET PROFIT(HY) At CNY 37.56 MM has Grown at -65.94%
OPERATING CASH FLOW(Y) Lowest at CNY 210.71 MM
NET SALES(9M) At CNY 874.25 MM has Grown at -10.36%

With ROE of 2.57%, it has a very expensive valuation with a 9.92 Price to Book Value

Over the past year, while the stock has generated a return of 19.88%, its profits have fallen by -60.5%
At the current price, the company has a high dividend yield of 0.2

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is BrightGene Bio-Medical Technology Co., Ltd. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

BrightGene Bio-Medical Technology Co., Ltd.

-32.99%

0.36

58.00%

China Shanghai Composite

21.43%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.01%

EBIT Growth (5y)

-23.73%

EBIT to Interest (avg)

25.45

Debt to EBITDA (avg)

3.56

Net Debt to Equity (avg)

0.57

Sales to Capital Employed (avg)

0.25

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

12.40%

Pledged Shares

Institutional Holding

ROCE (avg)

7.70%

ROE (avg)

9.15%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

510

Industry P/E

Price to Book Value

7.35

EV to EBIT

391.38

EV to EBITDA

114.03

EV to Capital Employed

4.81

EV to Sales

15.60

PEG Ratio

Dividend Yield

0.25%

ROCE (Latest)

1.23%

ROE (Latest)

1.44%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET SALES(HY)

At CNY 674.33 MM has Grown at 21.57%

RAW MATERIAL COST(Y)

Fallen by -48.29% (YoY

CASH AND EQV(HY)

Highest at CNY 2,356.42 MM

-30What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 101.69 MM

PRE-TAX PROFIT(Q)

At CNY -5.37 MM has Fallen at -268.59%

ROCE(HY)

Lowest at 2.02%

INTEREST(Q)

At CNY 18.58 MM has Grown at 27.39%

INTEREST COVERAGE RATIO(Q)

Lowest at 46.86

OPERATING PROFIT(Q)

Lowest at CNY 8.71 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 2.68 %

NET PROFIT(Q)

At CNY 6.7 MM has Fallen at -34.15%

Here's what is working for BrightGene Bio-Medical Technology Co., Ltd.

Net Sales

At CNY 674.33 MM has Grown at 21.57%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Cash and Eqv

Highest at CNY 2,356.42 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -48.29% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for BrightGene Bio-Medical Technology Co., Ltd.

Pre-Tax Profit

At CNY -5.37 MM has Fallen at -268.59%

over average net sales of the previous four periods of CNY 3.19 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Operating Cash Flow

Lowest at CNY 101.69 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest

At CNY 18.58 MM has Grown at 27.39%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest Coverage Ratio

Lowest at 46.86

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Operating Profit

Lowest at CNY 8.71 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 2.68 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Net Profit

At CNY 6.7 MM has Fallen at -34.15%

over average net sales of the previous four periods of CNY 10.18 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)